Abstract: The specification discloses purine nucleotide analogues which modulate cardiac muscle contractility and possess vasodilator activity. In addition, related methods of administration and the identity of receptors that bind these compounds are disclosed.
Type:
Grant
Filed:
September 23, 1997
Date of Patent:
July 3, 2001
Assignee:
The Trustees of the University of Pennsylvania
Abstract: The invention relates to compounds of general structure (I) or salts thereof, wherein B is a nucleobase, X and Z independently are oxygen or sulphur, Y is hydrogen or hydroxy, which optionally may be protected, R1 is hydrocarbyl, which optionally is substituted with a functional group, R2 is hydrogen or hydrocarbyl, which optionally is substituted with a functional group, A is an electron withdrawing or electron donating group capable of moderating the acetal stability of compound (I), L1 and L2 are hydrocarbon linkers, which may be the same or different, L2, when present, being either (i) connected to L1 via the group A, or (ii) directly connected to L1, the group A then being connected to one of linkers L1 and L2, F is a dye label, Q is a coupling group for F, and l, m and n independently are 0 or 1, with the proviso that l is 1 when m is 1, and l is 1 and m is 1 when n is 1. The compounds of formula (I) are useful as deactivatable chain extension terminators.
Abstract: Novel nucleoside analogs, such as 3-(&bgr;-D-Ribofuranosyl)-2-fluoropyridine, 3-(&bgr;-D-Ribofuranosyl)-pyridin-2-one, 3-(&bgr;-D-Ribofuranosyl)-pyridin-2-(4-nitrophenylethyl)-one, 3-(&agr;-D-Ribofuranosyl)-2-fluoropyridine, 5-(&bgr;-D-Ribofuranosyl)-2-bromopyridine, 5-(&agr;-D-Ribofuranosyl)-2-bromopyridine, 5-(&bgr;-D-Ribofuranosyl)-pyridin-2-one, 5-(&agr;-D-Ribofuranosyl)-pyridin-2-one, 5-(&bgr;-D-Ribofuranosyl)-2-aminopyridine, 5-(&bgr;-D-Ribofuranosyl)-pyridin-2-(4-nitrophenylethyl)-one, and 5-(&agr;-D-Ribofuranosyl)-2-aminopyridine; process for their synthesis and incorporation into polynucleotides.
Type:
Grant
Filed:
November 21, 1997
Date of Patent:
June 19, 2001
Assignee:
Ribozyme Pharmaceuticals, Inc.
Inventors:
Jasenka Matulic-Adamic, Leonid Beigelman, Alexander Karpeisky
Abstract: A method for the stepwise creation of phosphodiester bonds between desired nucleosides resulting in the synthesis of polynucleotides having a predetermined nucleotide sequence by preparing an initiation substrate containing a free and unmodified 3′-hydroxyl group; attaching a mononucleotide selected according to the order of the predetermined nucleotide sequence to the 3′-hydroxyl of the initiating substrate in a solution containing a catalytic amount of an enzyme capable of catalyzing the 5′ to 3′ phosphodiester linkage of the 5′-phosphate of the mononucleotide to the 3′-hydroxyl of the initiating substrate, wherein the mononucleotide contains a protected 3′-hydroxyl group, whereby the protected mononucleotide is covalently linked to the initiating substrate and further additions are hindered by the 3′-hydroxyl protecting group. Methods in which a mononucleotide immobilized on a solid support is added to a free polynucleotide chain are also disclosed.
Abstract: A method for the stepwise creation of phosphodiester bonds between desired nucleosides resulting in the synthesis of polynucleotides having a predetermined nucleotide sequence by preparing an initiation substrate containing a free and unmodified 3′-hydroxyl group; attaching a mononucleotide selected according to the order of the predetermined nucleotide sequence to the 3′-hydroxyl of the initiating substrate in a solution containing a catalytic amount of an enzyme capable of catalyzing the 5′ to 3′ phosphodiester linkage of the 5′-phosphate of the mononucleotide to the 3′-hydroxyl of the initiating substrate, wherein the mononucleotide contains a protected 3′-hydroxyl group, whereby the protected mononucleotide is covalently linked to the initiating substrate and further additions are hindered by the 3′-hydroxyl protecting group. Methods in which a mononucleotide immobilized on a solid support is added to a free polynucleotide chain are also disclosed.
Abstract: The invention concerns pyrrolo-[3,2-d]pyrimidine, pyrazolo-[4,3-d]pyrimidine and pyrimidine-furanosides i.e. so-called C-nucleosides of the general formulae I-V
or appropriate derivatives as well as processes for their production. The compounds are in particular suitable as substrates for RNA or DNA polymerases and can thus be incorporated into RNA or DNA oligonucleotides. Therefore the compounds are especially suitable for labelling and for detecting nucleic acids and for DNA sequencing.
Type:
Grant
Filed:
September 15, 1997
Date of Patent:
January 16, 2001
Assignee:
Roche Diagnostics GmbH
Inventors:
Klaus M{umlaut over (u)}hlegger, Herbert Von der Eltz, Frank Seela, Helmet Rosemeyer
Abstract: Modified pyrimidine nucleotides derivatized at C5 to contain a functional group that mimics the property of a naturally occurring amino acid residues are provided. DNA molecules containing the modified nucleotides are also provided.